CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of careWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)

Name (Synonyms) Correlation
drug849 Enhanced Chronic Disease Self-management program Wiki 1.00
drug2326 Standard of care Wiki 0.23

Correlated MeSH Terms (2)

Name (Synonyms) Correlation
D002908 Chronic Disease NIH 0.32
D006973 Hypertension NIH 0.28

Correlated HPO Terms (1)

Name (Synonyms) Correlation
HP:0000822 Hypertension HPO 0.28

There is one clinical trial.

Clinical Trials

1 A Randomized Controlled Trial to Evaluate the Outcomes With Aggrenox in Patients With SARS-CoV-2 Infection

The purpose of this study is to explore the efficacy of Aggrenox in patients with SARS-CoV-2 infection with symptoms consistent with COVID-19. An anticipated total of 132 participants will be randomly divided almost equally into 2 groups: one group will receive Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally along with the standard of care and the other group with receive the standard of care only but no Dipyridamole ER 200mg/ Aspirin 25mg. Participants will be screened, enrolled, receive treatment, and followed for 28 days. The clinical and laboratory outcomes of all the participants enrolled in the study will be evaluated at the end of the study to explore if there is any difference in the outcomes between 2 groups.

NCT04410328 Covid19 Drug: Dipyridamole ER 200mg/ Aspirin 25mg orally/enterally AND Standard of care Other: Standard of care

Primary Outcomes

Description: Change in composite COVID ordinal scale at day 15. Ordinal scale: 1) not hospitalized with resumption of normal activities; 2) not hospitalized, but unable to resume normal activities; 3) hospitalized, not requiring oxygen; 4) hospitalized, requiring oxygen; 5) hospitalized, requiring high-flow oxygen therapy, or noninvasive ventilation; 6) hospitalized, requiring invasive ventilation; 7) ventilation plus additional organ support such as pressors, renal replacement therapy and ECMO and 8) death. COVID Ordinal Scale ranges from 1 to 8, with score 1 on the scale corresponds to an ambulatory patient with minimal symptoms and score 8 on the scale corresponds to death.

Measure: Covid (Coronavirus Disease-19) Ordinal Scale

Time: 15 days

Secondary Outcomes

Description: All-cause mortality assessed on day 15.

Measure: Mortality

Time: 15 days

Description: All-cause mortality assessed on day 28.

Measure: Mortality

Time: 28 days

Description: Supplemental Oxygen-free days

Measure: Supplemental Oxygen

Time: 28 days

Description: Invasive-ventilator-free days

Measure: Invasive-ventilator

Time: 28 days

Description: ICU-free days

Measure: ICU stay

Time: 28 days

Description: Hospital-free days

Measure: Hospital stay

Time: 28 days

Description: Decrease in the markers D-dimer/ Ferritin/ C-reactive protein

Measure: Inflammatory markers

Time: 15 days

Description: Thromboembolic complications including stroke

Measure: Thromboembolic complications

Time: 28 days

Description: COVID ordinal scale

Measure: COVID ordinal scale

Time: 28 days

No related HPO nodes (Using clinical trials)